Wir sind mit live!
Mehr erfahren
WWB
Windward Bio Group
Profil: Windward Bio Group AG is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis. Its flagship program is WIN378, a potentially novel, long-acting, anti-TSLP monoclonal antibody. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bi-specific, which has therapeutic application across immunological diseases.
Nachrichten
Positiv
Neutral
Negativ
Stimmung
3 Monate
Positiv
0 %
Neutral
0 %
Negativ
0 %
Für WWB liegen uns keine aktuellen Nachrichtenartikel vor.
Kursdiagramme mit Lightweight Charts™ umgesetzt